Project description:Pancreatic cancer is a devastating disease with both local invasion and distant metastasis. Identifying the genes expressed in liver metastases and signatures of metastatic progression would therefore be of particular importance as they could aid in both recurrence prediction as well as representing novel therapeutic targets. Keywords: Gene expression profiling We have performed microarray gene expression analysis of normal pancreas, primary pancreatic ductal adenocarcinoma (PDAC), normal liver, and pancreatic liver metastases to identify potential therapeutic targets. This dataset is part of the TransQST collection.
Project description:This is a dataset generated by the Drosophila Regulatory Elements modENCODE Project led by Kevin P. White at the University of Chicago. It contains ChIP-chip data on Agilent 244K dual-color arrays for antibody: H3K9Ac at 12 different time-points of Drosophila development. Current Dataset: [GSM386138..GSM386146]: ChIP-chip of H3K9AC in Drosophila embryos at 12-16 hours of development [GSM386148..GSM386156]: ChIP-chip of H3K9AC in Drosophila L1 larvae [GSM386158..GSM386166]: ChIP-chip of H3K9AC in Drosophila L2 larvae [GSM386168..GSM386176]: ChIP-chip of H3K9AC in Adult female Drosophila [GSM418290..GSM418298]: ChIP-chip of H3K9AC in Adult male Drosophila [GSM442311..GSM442316]: ChIP-chip of H3K9AC in Drosophila embryos at 8-12 hours of development [GSM442317..GSM442325]: ChIP-chip of H3K9AC in Adult male Drosophila - Set2 [GSM442326..GSM442334]: ChIP-chip of H3K9AC in Pupae [GSM442335..GSM442343]: ChIP-chip of H3K9AC in L3 [GSM442344..GSM442352]: ChIP-chip of H3K9AC in Drosophila embryos at 20-24 hours of development [GSM442353..GSM442361]: ChIP-chip of H3K9AC in Drosophila embryos at 4-8 hours of development [GSM442362..GSM442370]: ChIP-chip of H3K9AC in Drosophila embryos at 0-4 hours of development For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODEDataReleasePolicyFinal2008.pdf
Project description:This is a dataset generated by the Drosophila Regulatory Elements modENCODE Project led by Kevin P. White at the University of Chicago. It contains ChIP-chip data on Agilent 244K dual-color arrays for antibody: H3K9Ac at 12 different time-points of Drosophila development. Current Dataset: [GSM386138..GSM386146]: ChIP-chip of H3K9AC in Drosophila embryos at 12-16 hours of development [GSM386148..GSM386156]: ChIP-chip of H3K9AC in Drosophila L1 larvae [GSM386158..GSM386166]: ChIP-chip of H3K9AC in Drosophila L2 larvae [GSM386168..GSM386176]: ChIP-chip of H3K9AC in Adult female Drosophila [GSM418290..GSM418298]: ChIP-chip of H3K9AC in Adult male Drosophila [GSM442311..GSM442316]: ChIP-chip of H3K9AC in Drosophila embryos at 8-12 hours of development [GSM442317..GSM442325]: ChIP-chip of H3K9AC in Adult male Drosophila - Set2 [GSM442326..GSM442334]: ChIP-chip of H3K9AC in Pupae [GSM442335..GSM442343]: ChIP-chip of H3K9AC in L3 [GSM442344..GSM442352]: ChIP-chip of H3K9AC in Drosophila embryos at 20-24 hours of development [GSM442353..GSM442361]: ChIP-chip of H3K9AC in Drosophila embryos at 4-8 hours of development [GSM442362..GSM442370]: ChIP-chip of H3K9AC in Drosophila embryos at 0-4 hours of development For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODEDataReleasePolicyFinal2008.pdf For each combination of time-point and antibody, triplicate ChIP experiments have been performed and hybridized on Agilent 244K arrays. 3 arrays per genome have been used so that each time-point is a set of 9 tiling arrays.
Project description:Understanding how prostate cancer cells adapt to AR-targeted interventions is critical for identifying novel drug targets to improve the clinical management of treatment-resistant disease. Our study revealed an enzalutamide-induced epigenetic plasticity towards pro-survival signaling, and uncovered circadian regulator ARNTL as an acquired vulnerability after AR inhibition, presenting a novel clinical lead for therapeutic development.
Project description:Understanding how prostate cancer cells adapt to AR-targeted interventions is critical for identifying novel drug targets to improve the clinical management of treatment-resistant disease. Our study revealed an enzalutamide-induced epigenetic plasticity towards pro-survival signaling, and uncovered circadian regulator ARNTL as an acquired vulnerability after AR inhibition, presenting a novel clinical lead for therapeutic development.
